Literature DB >> 22828605

The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Hirotsugu Uehara1, Simon J Hocart, Nieves González, Samuel A Mantey, Tomoo Nakagawa, Tatsuro Katsuno, David H Coy, Robert T Jensen.   

Abstract

There is increased interest in the Bn-receptor family because they are frequently over/ectopically expressed by tumors and thus useful as targets for imaging or receptor-targeted-cytotoxicity. The synthetic Bn-analog, [D-Tyr(6), β-Ala(11), Phe(13), Nle(14)]Bn(6-14) [Univ.Lig] has the unique property of having high affinity for all three human BNRs (GRPR, NMBR, BRS-3), and thus could be especially useful for this approach. However, the molecular basis of this property is unclear and is the subject of this study. To accomplish this, site-directed mutagenesis was used after identifying potentially important amino acids using sequence homology analysis of all BnRs with high affinity for Univ.Lig compared to the Cholecystokinin-receptor (CCK(A)R), which has low affinity. Using various criteria 74 amino acids were identified and 101 mutations made in GRPR by changing each to those of CCK(A)R or to alanine. 22 GRPR mutations showed a significant decrease in affinity for Univ.Lig (>2-fold) with 2 in EC2[D97N, G112V], 1 in UTM6[Y284A], 2 in EC4[R287N, H300S] showing >10-fold decrease in Univ.Lig affinity. Additional mutations were made to explore the molecular basis for these changes. Our results show that high affinity for Univ.Lig by human Bn-receptors requires positively charged amino acids in extracellular (EC)-domain 4 and to a lesser extent EC2 and EC3 suggesting charge-charge interactions may be particularly important for determining the general high affinity of this ligand. Furthermore, transmembrane amino acids particularly in UTM6 are important contributing both charge-charge interactions as well as interaction with a tyrosine residue in close proximity suggesting possible receptor-peptide cation-π or H-bonding interactions are also important for determining its high affinity. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22828605      PMCID: PMC3433740          DOI: 10.1016/j.bcp.2012.07.010

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  77 in total

1.  Discovery of a high affinity radioligand for the human orphan receptor, bombesin receptor subtype 3, which demonstrates that it has a unique pharmacology compared with other mammalian bombesin receptors.

Authors:  S A Mantey; H C Weber; E Sainz; M Akeson; R R Ryan; T K Pradhan; R P Searles; E R Spindel; J F Battey; D H Coy; R T Jensen
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

2.  Cation-pi interactions in aromatics of biological and medicinal interest: electrostatic potential surfaces as a useful qualitative guide.

Authors:  S Mecozzi; A P West; D A Dougherty
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-01       Impact factor: 11.205

3.  Effect of gastrin-releasing peptide receptor number on receptor affinity, coupling, degradation, and modulation.

Authors:  T Tsuda; T Kusui; W Hou; R V Benya; M A Akeson; G S Kroog; J F Battey; R T Jensen
Journal:  Mol Pharmacol       Date:  1997-05       Impact factor: 4.436

4.  Identification of four amino acids in the gastrin-releasing peptide receptor that are required for high affinity agonist binding.

Authors:  M Akeson; E Sainz; S A Mantey; R T Jensen; J F Battey
Journal:  J Biol Chem       Date:  1997-07-11       Impact factor: 5.157

5.  Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors.

Authors:  J T Lin; D H Coy; S A Mantey; R T Jensen
Journal:  Eur J Pharmacol       Date:  1995-12-27       Impact factor: 4.432

6.  Modeling the G-protein-coupled neuropeptide Y Y1 receptor agonist and antagonist binding sites.

Authors:  P Du; J A Salon; J A Tamm; C Hou; W Cui; M W Walker; N Adham; D S Dhanoa; I Islam; P J Vaysse; B Dowling; Y Shifman; N Boyle; H Rueger; T Schmidlin; Y Yamaguchi; T A Branchek; R L Weinshank; C Gluchowski
Journal:  Protein Eng       Date:  1997-02

7.  Bombesin receptor structure and expression in human lung carcinoma cell lines.

Authors:  Z Fathi; J W Way; M H Corjay; J Viallet; E A Sausville; J F Battey
Journal:  J Cell Biochem Suppl       Date:  1996

8.  Moving from the orphanin FQ receptor to an opioid receptor using four point mutations.

Authors:  F Meng; L P Taylor; M T Hoversten; Y Ueda; A Ardati; R K Reinscheid; F J Monsma; S J Watson; O Civelli; H Akil
Journal:  J Biol Chem       Date:  1996-12-13       Impact factor: 5.157

Review 9.  Cation-pi interactions in chemistry and biology: a new view of benzene, Phe, Tyr, and Trp.

Authors:  D A Dougherty
Journal:  Science       Date:  1996-01-12       Impact factor: 47.728

10.  Identification of the site in the substance P (NK-1) receptor for modulation of peptide binding by sulfhydryl reagents.

Authors:  H Li; P Hsu; B S Sachais; J E Krause; S E Leeman; N D Boyd
Journal:  J Biol Chem       Date:  1996-01-26       Impact factor: 5.157

View more
  3 in total

1.  The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3.

Authors:  Irene Ramos-Alvarez; Tatiana Iordanskaia; Samuel A Mantey; Robert T Jensen
Journal:  J Pharmacol Exp Ther       Date:  2022-05-29       Impact factor: 4.402

2.  Molecular basis for high affinity and selectivity of peptide antagonist, Bantag-1, for the orphan BB3 receptor.

Authors:  Taichi Nakamura; Irene Ramos-Álvarez; Tatiana Iordanskaia; Paola Moreno; Samuel A Mantey; R T Jensen
Journal:  Biochem Pharmacol       Date:  2016-06-23       Impact factor: 5.858

3.  GRPR-targeted Protein Contrast Agents for Molecular Imaging of Receptor Expression in Cancers by MRI.

Authors:  Fan Pu; Jingjuan Qiao; Shenghui Xue; Hua Yang; Anvi Patel; Lixia Wei; Khan Hekmatyar; Mani Salarian; Hans E Grossniklaus; Zhi-Ren Liu; Jenny J Yang
Journal:  Sci Rep       Date:  2015-11-18       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.